Potential risk for medication error between ZALTRAP® (aflibercept, formulated for intravenous use) and EYLEA® (aflibercept, formulated for intravitreal use)

Sanofi-Aventis Singapore Pte Ltd would like to alert healthcare professionals to the potential risk of medication error between Zaltrap® and Eylea®.Both products contain the active ingredient, aflibercept, but Zaltrap® is formulated for intravenous use only while Eylea® is formulated for intravitreal use only. Zaltrap® must only be administered through intravenous injection (after dilution) and ophthalmic or intravitreal use is contraindicated due to its hyperosmotic properties. Please refer to the latest approved local package insert for Zaltrap® for more information on the correct administration.

 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.